دراسة لتقييم السلامة طويلة الأمد لدى المشاركين الذين شاركوا في تجارب سريرية أخرى للوسباتيرسيبت (ACE-536)
This study is checking the long-term safety of a medicine called luspatercept. It's for adults, aged 18 and over, who have blood conditions like Myelodysplastic Syndromes (MDS), Beta-thalassemia, or Myelofibrosis and have already been part of another luspatercept study. If your doctor thinks you're benefiting from luspatercept, or if you were on a placebo but could now benefit from the active medicine, you might be able to join. The main goal is to keep an eye on your health and any side effects over a long period, which could be several years, as you continue with or finish your treatment.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is like a continuation for people who have already been taking part in a clinical trial for a medicine called luspatercept. Luspatercept is a treatment for certain blood conditions such as Myelodysplastic Syndromes (MDS), a type of blood cancer; Beta-thalassemia, which is an inherited blood disorder; and Myelofibrosis, where the bone marrow is replaced by scar tissue. The main purpose of this new study is to carefully watch how safe luspatercept is over a much longer period of time.
Taking part in this study means you’ll either continue receiving luspatercept if your doctor thinks it's helping you, or, if you were on a dummy treatment (placebo) in a previous study, you might switch to receiving luspatercept. If you've already finished treatment in a previous study, you might join this one for long-term health checks, to see how you are doing over many years. This helps researchers understand the full picture of the medicine's safety.
By carefully checking on participants for several years, doctors and researchers can learn a lot about any potential long-term side effects or benefits of luspatercept. This information is really important for making sure new medicines are as safe and effective as possible for everyone who might need them in the future. The study will pay close attention to your general health and any changes, including checking for any new health problems that might develop.
النقاط الرئيسية
- This study is for checking the long-term safety of luspatercept.
- It's for people already in a luspatercept study.
- You might continue treatment, start it, or just have long-term health checks.
- The study involves regular visits and monitoring over several years.
- It aims to gather important information about the medicine's effects over time.
- Your general health and any new problems will be closely monitored.
من قد يكون مؤهلاً؟
To be able to join this study, you must be at least 18 years old and already taking part in another study involving luspatercept. You also need to be willing to come to all the study appointments and follow the study's instructions.
There are a few main ways you might fit in. Firstly, if you're currently receiving luspatercept in another study and your doctor feels it’s still helping you, you might be able to continue on it in this new study. Secondly, if you were on a dummy treatment (placebo) in your previous study and it's decided that you could benefit from luspatercept, you might switch to receiving the actual medicine. Finally, if you've already finished treatment in a previous luspatercept study but are still having your health checked, you might join this study to continue those long-term health checks.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك 18 سنة أو أكثر؟
- Are you currently taking part in another study for luspatercept, or have you recently finished one?
- Is your doctor recommending you continue with luspatercept, start it, or continue with long-term follow-up after your previous study?
- Are you able and willing to attend all study appointments and follow instructions?
ماذا يتضمن المشاركة؟
If you join this study, your journey will have different stages. There's an initial 'Transition Phase' which involves one initial check-up visit. Depending on your situation from your previous study, you will then either enter a 'Treatment Phase' or a 'Follow-up Phase'.
If you enter the 'Treatment Phase', you will continue to receive luspatercept at the same dose and schedule you were on in your previous study. After your last dose of luspatercept, you will have a '42 Day Safety Follow-up Visit' where doctors will check your health and any side effects. The 'Follow-up Phase' is much longer; doctors will keep in touch every 6 months for at least 5 years from your very first dose of luspatercept (in your original study), or for 3 years after your last dose, whichever is longer. During this long-term follow-up, they will monitor your general health and look for any new health conditions. The study will continue until all participants have completed 5 years of being in the study, including both treatment and follow-up.
المخاطر والفوائد المحتملة
Locations (143)
- Local Institution - 968الرمز البريدي المؤكدلوس أنجلوس، الولايات المتحدة· مكتمل
- Local Institution - 971الرمز البريدي المؤكدأوكلاند، الولايات المتحدة· مكتمل
- Local Institution - 978الرمز البريدي المؤكدستانفورد، الولايات المتحدة· مكتمل
- Local Institution - 975الرمز البريدي المؤكدتامبا، الولايات المتحدة· مكتمل
- Local Institution - 970الرمز البريدي المؤكدشيكاغو، الولايات المتحدة· مكتمل
- Local Institution - 973الرمز البريدي المؤكدبوسطن، الولايات المتحدة· مكتمل
- Local Institution - 961الرمز البريدي المؤكدديترويت، الولايات المتحدة· مكتمل
- Local Institution - 969الرمز البريدي المؤكدنيويورك، الولايات المتحدة· مكتمل
- Local Institution - 967الرمز البريدي المؤكدكليفلاند، الولايات المتحدة· مكتمل
- Local Institution - 972الرمز البريدي المؤكدفيلادلفيا، الولايات المتحدة· مكتمل
- Vanderbilt - Ingram Cancer Centerالرمز البريدي المؤكدناشفيل، الولايات المتحدة· منسحب
- The University of Texas - MD Anderson Cancer Centerالرمز البريدي المؤكدهيوستن، الولايات المتحدة· منسحب
أسئلة شائعة
ما هو الهدف الرئيسي من هذه الدراسة؟
The main purpose is to evaluate the long-term safety of the medicine luspatercept in people who have already been part of another study for this treatment.
من يمكنه المشاركة في هذه الدراسة؟
Adults aged 18 or over who are currently in or have recently completed another clinical trial for luspatercept and meet specific health criteria, as determined by their doctor.
What kind of conditions is luspatercept used for?
Luspatercept is being studied for blood conditions like Myelodysplastic Syndromes (MDS), Beta-thalassemia, and Myelofibrosis.
ما هي المدة التي سأكون فيها في هذه الدراسة؟
This study involves long-term follow-up, which could be for at least 5 years from your first dose of luspatercept or 3 years after your last dose, whichever is longer.
ماذا لو قررت أنني لا أريد الاستمرار في الدراسة؟
You are free to leave the study at any time, for any reason. Your decision will not affect your regular medical care.
كيفية معرفة المزيد
مركز اتصال التجارب السريرية لشركة BMS www.BMSClinicalTrials.com
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.